| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.80 [0.71, 0.91] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | crucial | - |
| deaths (OS) (extension) | 0.72 [0.60, 0.87] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| progression or deaths (PFS) | 1.11 [0.77, 1.61] | | < 1 | | 89% | 2 studies (2/-) | 28.7 % | some concern | not evaluable | moderate | important | - |
| objective responses (ORR) | 0.59 [0.23, 1.56] | | > 1 | | 93% | 2 studies (2/-) | 14.5 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.31 [0.22, 0.44] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| AE (grade 3-4) | 1.00 [0.69, 1.46] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
| AE leading to death (grade 5) | 1.02 [0.69, 1.50] | | < 1 | | 0% | 2 studies (2/-) | 46.1 % | some concern | not evaluable | moderate | non important | - |
| AE leading to treatment discontinuation (any grade) | 0.68 [0.20, 2.35] | | < 1 | | 95% | 2 studies (2/-) | 72.8 % | some concern | not evaluable | moderate | non important | - |
| TRAE (any grade) | 0.18 [0.01, 2.64] | | < 1 | | 96% | 2 studies (2/-) | 89.3 % | some concern | not evaluable | moderate | non important | - |
| TRAE (grade 3-4) | 0.32 [0.03, 3.76] | | < 1 | | 99% | 2 studies (2/-) | 81.6 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to death (grade 5) | 0.78 [0.20, 3.08] | | < 1 | | 66% | 2 studies (2/-) | 63.9 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Adrenal insufficiency TRAE (grade 3-4) | 1.47 [0.11, 19.25] | | < 1 | | 0% | 2 studies (2/-) | 38.4 % | some concern | not evaluable | moderate | non important | - |
| Anaemia TRAE (grade 3-4) | 0.25 [0.01, 8.25] | | < 1 | | 95% | 2 studies (2/-) | 78.0 % | some concern | not evaluable | moderate | non important | - |
| Asthenia TRAE (grade 3-4) | 0.54 [0.08, 3.85] | | < 1 | | 65% | 2 studies (2/-) | 73.0 % | some concern | not evaluable | moderate | non important | - |
| Blood and lymphatic system disorders TRAE (grade 3-4) | 0.18 [0.00, 9.02] | | < 1 | | 98% | 2 studies (2/-) | 79.9 % | some concern | not evaluable | moderate | non important | - |
| Blood creatinine increased TRAE (grade 3-4) | 1.49 [0.11, 19.48] | | < 1 | | 0% | 2 studies (2/-) | 38.1 % | some concern | not evaluable | moderate | non important | - |
| Colitis TRAE (grade 3-4) | 1.00 [0.25, 4.01] | | < 1 | | 0% | 2 studies (2/-) | 50.1 % | some concern | not evaluable | moderate | non important | - |
| Constipation TRAE (grade 3-4) | 1.00 [0.06, 15.99] | | < 1 | | 0% | 2 studies (2/-) | 50.1 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite TRAE (grade 3-4) | 0.51 [0.04, 6.46] | | < 1 | | 80% | 2 studies (2/-) | 69.6 % | some concern | not evaluable | moderate | non important | - |
| Diarrhoea TRAE (grade 3-4) | 0.43 [0.13, 1.42] | | < 1 | | 0% | 2 studies (2/-) | 91.7 % | some concern | not evaluable | moderate | non important | - |
| Endocrine disorders TRAE (grade 3-4) | 3.70 [0.39, 35.06] | | < 1 | | 0% | 2 studies (2/-) | 12.9 % | some concern | not evaluable | moderate | non important | - |
| Fatigue TRAE (grade 3-4) | 0.74 [0.11, 5.15] | | < 1 | | 85% | 2 studies (2/-) | 62.1 % | some concern | not evaluable | moderate | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 0.07 [0.02, 0.23] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| General disorders and administration site conditions TRAE (grade 3-4) | 0.62 [0.06, 5.93] | | < 1 | | 95% | 2 studies (2/-) | 66.1 % | some concern | not evaluable | moderate | non important | - |
| Hepatitis TRAE (grade 3-4) | 2.91 [0.29, 28.79] | | < 1 | | 0% | 2 studies (2/-) | 18.2 % | some concern | not evaluable | moderate | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 1.47 [0.11, 19.25] | | < 1 | | 0% | 2 studies (2/-) | 38.4 % | some concern | not evaluable | moderate | non important | - |
| Hypophysitis TRAE (grade 3-4) | 2.00 [0.18, 22.10] | | < 1 | | 0% | 2 studies (2/-) | 28.8 % | some concern | not evaluable | moderate | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.04 [0.02, 52.60] | | < 1 | | 0% | 1 study (1/-) | 49.2 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 0.33 [0.11, 1.02] | | < 1 | | 0% | 2 studies (2/-) | 97.2 % | some concern | not evaluable | moderate | non important | - |
| Leucopenia TRAE (grade 3-4) | 0.17 [0.01, 2.60] | | < 1 | | 73% | 2 studies (2/-) | 89.8 % | some concern | not evaluable | moderate | non important | - |
| Metabolism and nutrition disorders TRAE (grade 3-4) | 0.48 [0.15, 1.62] | | < 1 | | 89% | 2 studies (2/-) | 88.0 % | some concern | not evaluable | moderate | non important | - |
| Mucosal inflammation TRAE (grade 3-4) | 0.56 [0.04, 8.18] | | < 1 | | 91% | 2 studies (2/-) | 66.3 % | some concern | not evaluable | moderate | non important | - |
| Myocarditis TRAE (grade 3-4) | 1.49 [0.11, 19.48] | | < 1 | | 0% | 2 studies (2/-) | 38.1 % | some concern | not evaluable | moderate | non important | - |
| Myositis TRAE (grade 3-4) | 0.50 [0.05, 5.51] | | < 1 | | 0% | 2 studies (2/-) | 71.4 % | some concern | not evaluable | moderate | non important | - |
| Nausea TRAE (grade 3-4) | 0.22 [0.01, 6.71] | | < 1 | | 82% | 2 studies (2/-) | 80.5 % | some concern | not evaluable | moderate | non important | - |
| Nephritis TRAE (grade 3-4) | 2.32 [0.20, 26.51] | | < 1 | | 0% | 2 studies (2/-) | 25.0 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia TRAE (grade 3-4) | 0.09 [0.00, 10.60] | | < 1 | | 91% | 2 studies (2/-) | 83.1 % | some concern | not evaluable | moderate | non important | - |
| Pancreatitis TRAE (grade 3-4) | 1.49 [0.11, 19.48] | | < 1 | | 0% | 2 studies (2/-) | 38.1 % | some concern | not evaluable | moderate | non important | - |
| Pneumonitis TRAE (grade 3-4) | 2.52 [0.79, 8.08] | | < 1 | | 0% | 2 studies (2/-) | 6.0 % | some concern | not evaluable | moderate | non important | - |
| Rash TRAE (grade 3-4) | 0.09 [0.03, 0.28] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| Severe skin reaction TRAE (grade 3-4) | 0.20 [0.08, 0.53] | | < 1 | | 26% | 2 studies (2/-) | 99.9 % | some concern | not evaluable | moderate | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 0.11 [0.03, 0.35] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Stomatitis TRAE (grade 3-4) | 0.43 [0.01, 19.84] | | < 1 | | 86% | 2 studies (2/-) | 66.5 % | some concern | not evaluable | moderate | non important | - |
| Thrombocytopenia TRAE (grade 3-4) | 0.23 [0.01, 5.94] | | < 1 | | 90% | 2 studies (2/-) | 81.1 % | some concern | not evaluable | moderate | non important | - |
| Thyroiditis TRAE (grade 3-4) | 1.00 [0.06, 15.99] | | < 1 | | 0% | 2 studies (2/-) | 50.1 % | some concern | not evaluable | moderate | non important | - |
| Uveitis TRAE (grade 3-4) | 1.00 [0.06, 15.99] | | < 1 | | 0% | 2 studies (2/-) | 50.1 % | some concern | not evaluable | moderate | non important | - |
| Vomiting TRAE (grade 3-4) | 0.52 [0.04, 7.08] | | < 1 | | 66% | 2 studies (2/-) | 68.6 % | some concern | not evaluable | moderate | non important | - |
| Weight decreased TRAE (grade 3-4) | 1.49 [0.24, 9.20] | | < 1 | | 0% | 2 studies (2/-) | 33.3 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-4) endpoints 00 |
| Abdominal pain AE (grade 3-4) | 0.31 [0.08, 1.14] | | < 1 | | 0% | 2 studies (2/-) | 96.1 % | some concern | not evaluable | moderate | non important | - |
| Acute kidney injury AE (grade 3-4) | 2.26 [0.69, 7.40] | | < 1 | | 0% | 2 studies (2/-) | 8.9 % | some concern | not evaluable | moderate | non important | - |
| Anaemia AE (grade 3-4) | 0.64 [0.10, 4.24] | | < 1 | | 96% | 2 studies (2/-) | 67.9 % | some concern | not evaluable | moderate | non important | - |
| Asthenia AE (grade 3-4) | 0.62 [0.19, 2.01] | | < 1 | | 53% | 2 studies (2/-) | 78.5 % | some concern | not evaluable | moderate | non important | - |
| Blood and lymphatic system disorders AE (grade 3-4) | 0.38 [0.03, 4.87] | | < 1 | | 99% | 2 studies (2/-) | 76.8 % | some concern | not evaluable | moderate | non important | - |
| Decreased appetite AE (grade 3-4) | 0.67 [0.14, 3.15] | | < 1 | | 75% | 2 studies (2/-) | 69.3 % | some concern | not evaluable | moderate | non important | - |
| Diarrhoea AE (grade 3-4) | 0.56 [0.13, 2.37] | | < 1 | | 60% | 2 studies (2/-) | 78.4 % | some concern | not evaluable | moderate | non important | - |
| Dyspnoea AE (grade 3-4) | 1.82 [0.66, 4.99] | | < 1 | | 0% | 2 studies (2/-) | 12.3 % | some concern | not evaluable | moderate | non important | - |
| Fatigue AE (grade 3-4) | 0.99 [0.40, 2.45] | | < 1 | | 63% | 2 studies (2/-) | 50.8 % | some concern | not evaluable | moderate | non important | - |
| Febrile neutropenia AE (grade 3-4) | 0.27 [0.01, 13.91] | | < 1 | | 87% | 2 studies (2/-) | 73.8 % | some concern | not evaluable | moderate | non important | - |
| Gastrointestinal disorders AE (grade 3-4) | 0.69 [0.17, 2.75] | | < 1 | | 94% | 2 studies (2/-) | 70.2 % | some concern | not evaluable | moderate | non important | - |
| General disorders and administration site conditions AE (grade 3-4) | 0.86 [0.22, 3.39] | | < 1 | | 93% | 2 studies (2/-) | 58.8 % | some concern | not evaluable | moderate | non important | - |
| Hypertension AE (grade 3-4) | 11.64 [1.49, 90.62] | | < 1 | | 0% | 2 studies (2/-) | 1.0 % | some concern | not evaluable | moderate | non important | - |
| Hypothyroidism AE (grade 3-4) | 0.96 [0.02, 48.37] | | < 1 | | 0% | 1 study (1/-) | 50.9 % | NA | not evaluable | | non important | - |
| Increase AST AE (grade 3-4) | 0.39 [0.12, 1.27] | | < 1 | | 0% | 2 studies (2/-) | 94.1 % | some concern | not evaluable | moderate | non important | - |
| Leucopenia AE (grade 3-4) | 0.17 [0.01, 3.10] | | < 1 | | 75% | 2 studies (2/-) | 88.1 % | some concern | not evaluable | moderate | non important | - |
| Metabolism and nutrition disorders AE (grade 3-4) | 0.76 [0.35, 1.63] | | < 1 | | 86% | 2 studies (2/-) | 76.1 % | some concern | not evaluable | moderate | non important | - |
| Mucosal inflammation AE (grade 3-4) | 0.73 [0.10, 5.61] | | < 1 | | 90% | 2 studies (2/-) | 61.8 % | some concern | not evaluable | moderate | non important | - |
| Nausea AE (grade 3-4) | 0.21 [0.01, 6.94] | | < 1 | | 83% | 2 studies (2/-) | 80.5 % | some concern | not evaluable | moderate | non important | - |
| Nervous system disorders AE (grade 3-4) | 0.61 [0.28, 1.37] | | < 1 | | 62% | 2 studies (2/-) | 88.4 % | some concern | not evaluable | moderate | non important | - |
| Neutropenia AE (grade 3-4) | 0.11 [0.00, 6.60] | | < 1 | | 94% | 2 studies (2/-) | 84.9 % | some concern | not evaluable | moderate | non important | - |
| Pneumonitis AE (grade 3-4) | 0.78 [0.49, 1.27] | | < 1 | | 0% | 2 studies (2/-) | 83.8 % | some concern | not evaluable | moderate | non important | - |
| Rash AE (grade 3-4) | 0.09 [0.03, 0.28] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
| Renal and urinary disorders AE (grade 3-4) | 1.51 [0.67, 3.40] | | < 1 | | 0% | 2 studies (2/-) | 16.1 % | some concern | not evaluable | moderate | non important | - |
| Respiratory, thoracic and mediastinal disorders AE (grade 3-4) | 2.36 [1.48, 3.74] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
| Sepsis AE (grade 3-4) | 2.49 [0.77, 8.03] | | < 1 | | 0% | 2 studies (2/-) | 6.3 % | some concern | not evaluable | moderate | non important | - |
| Skin and subcutaneous tissue disorders AE (grade 3-4) | 1.42 [0.67, 3.00] | | < 1 | | 0% | 2 studies (2/-) | 18.1 % | some concern | not evaluable | moderate | non important | - |
| Stomatitis AE (grade 3-4) | 0.44 [0.01, 21.27] | | < 1 | | 86% | 2 studies (2/-) | 65.9 % | some concern | not evaluable | moderate | non important | - |
| Thrombocytopenia AE (grade 3-4) | 0.21 [0.01, 5.80] | | < 1 | | 90% | 2 studies (2/-) | 81.8 % | some concern | not evaluable | moderate | non important | - |
| Vascular disorders AE (grade 3-4) | 1.12 [0.55, 2.29] | | < 1 | | 48% | 2 studies (2/-) | 38.0 % | some concern | not evaluable | moderate | non important | - |
| Vomiting AE (grade 3-4) | 0.47 [0.05, 4.90] | | < 1 | | 77% | 2 studies (2/-) | 73.4 % | some concern | not evaluable | moderate | non important | - |
| Weight decreased AE (grade 3-4) | 2.53 [0.98, 6.58] | | < 1 | | 0% | 2 studies (2/-) | 2.8 % | some concern | not evaluable | moderate | non important | - |
